Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant Help Center Crisis
Powered By
Real members of MyLeukemiaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

Apakah jika imatinib tidak cocok bisa diketahui dengan jumlah trombosit yang menurun drastis? Dan obat apa yang disarankan untuk gantinya?

A MyLeukemiaTeam Member asked a question 💭
Indonesia
October 14, 2025
 · 
Reactions
A MyLeukemiaTeam Member

Apakah itu berarti setiap penderita cml harus bersiap ganti obat setelah jangka waktu tertentu?

October 17, 2025
A MyLeukemiaTeam Member

I had learned that medicines can control those bad cells and after the cells mutate the control is lost. The good news is that there are many types of medications that use different means to "control" the bad cells. I take a medication for my leukemia. I know the medication is good for 3 to 5 years or until the bad cells mutate.

October 16, 2025
MyLeukemiaTeam

Yes, a significant drop in platelet count (thrombocytopenia) can be one indication that Imatinib may not be working effectively for you. Sometimes Imatinib can stop working over time as CML cells become resistant to the drug.

If Imatinib resistance occurs, your doctor may either increase the Imatinib dose or switch you to Show Full Answer

Yes, a significant drop in platelet count (thrombocytopenia) can be one indication that Imatinib may not be working effectively for you. Sometimes Imatinib can stop working over time as CML cells become resistant to the drug.

If Imatinib resistance occurs, your doctor may either increase the Imatinib dose or switch you to a different TKI medication. Several alternative TKI medications are available if Imatinib isn't working well:

• Bosutinib (Bosulif)
• Ponatinib
• Asciminib
• Nilotinib (available as Tasigna or the newer Danziten)
• Dasatinib (Sprycel)

The newer formulation of Nilotinib (Danziten) has the advantage of being able to be taken with or without food, while most other TKIs must be taken on an empty stomach.

October 14, 2025

Related Questions

View All
Tyrosine Kinase Inhibitor Therapy vs. Chemotherapy: What Works Better for CML?
How Does CML Impact Life Expectancy? Survival Rates and More
Sticking To Leukemia Treatment Despite Drug Costs